Home Others Ottavio Arancio, MD, PhD

Ottavio Arancio, MD, PhD

Departments and departments

  • Institute for Pathology & Cell Biology

Academic appointments

  • Professor of Pathology & Cell Biology (in the Taub Institute)
Ottavio Arancio, MD, PhD

The research in my laboratory stems from my lifelong commitment to studying the mechanisms of synaptic plasticity. I'm interested in the cellular and molecular mechanisms underlying long-lasting changes in synaptic function in both normal, healthy brains and the brains of people with neurological disorders, particularly Alzheimer's disease (AD). Research in my lab focuses on the mechanisms by which oligoemric proteins, including amyloid-β (Aβ) peptides and tau, disrupt both memory formation and the regulation of long-term hippocampal potentiation (LTP), an activity-dependent model of synaptic plasticity, Es it is believed to be related to learning and memory. I am interested in how the regulation of gene activation and silencing, post-translational mechanisms, channel opening, intracellular calcium transients, and changes in the transmitter release machinery could be involved in basal synaptic transmission and plasticity.

education and training

  • MD, PhD, Medicine, University of Pisa (Italy)


  • 630 West 168th Street

    630 West 168th Street
    P&S 12-420D
    New York, NY 10032
    (212) 342-0533
    (212) 305-5498


a) Methods and compositions to improve memory. The invention relates to methods of improving memory by administering low doses of amyloid beta peptide. The invention also encompasses methods of increasing synaptic plasticity in a subject, which include administering low doses of amyloid beta peptide to the subject.

Filed on 03/30/09, patent application number: 12/414160

inventor : Arancio, O., Puzzo, D., Alberini, C., Mathews, P

b) Histone acetyltransferase activators and uses thereof. The researchers synthesized a new class of low molecular weight HAT activators with greater solubility and membrane permeability. The HAT activators work by promoting histone acetylation, as opposed to current therapies that aim to prevent deacetylation with HDAC inhibitors. In vivo studies showed that the compound not only crossed the blood-brain barrier, but also increased histone acetylation in the hippocampus and improved memory deficits in a mouse model of Alzheimer's disease.

Filed on December 10, 2010, patent application number: PCT / US2010 / 059925

Erfinder: Arancio, O., Francis Y, Fa 'M., Feng Y, Landry, DW, Deng, SX

c) Histone acetyltransferase modulators and uses thereof. The researchers synthesized new small molecules that increase or decrease the HATs, CBP and P300 differently.

Filed on 12/22/11, patent application number: PCT / US2011 / 066851

Erfinder: Arancio, O., Francis Y, Fa 'M., Feng Y, Landry, DW, Fiorito J., Luzac M., Deng, SX

d) Uses of histone acetyltransferase activators. The researchers have shown that low molecular weight HAT activators can be beneficial for cancer treatment.

Filed 6/11/12, patent application number: PCT / US2012 / 041907

Erfinder: Arancio, O., Francis Y.

e) Phosphodiesterase inhibitors and uses thereof. The researchers have synthesized a new class of small-molecule PDE5 inhibitors for therapeutic use in Alzheimer's disease.

what is categorical imperative

Filed on 09/29/09, patent application number: PCT / US2009 / 058813

Erfinder: Arancio, O., Landry, DW, Feng, Y., Deng, SX

f) Phosphodiesterase inhibitors and uses thereof. The invention provides new benzonaphthyridine derivatives that inhibit PDE5 for therapeutic use in Alzheimer's disease.

Filed on January 17, 2013, patent application number: PCT / US2013 / 021918

Erfinder: Orange, O., Landry, DW, Fiorito, J., Deng, SX, Wasmuth, A.

g) Novel phosphodiesterase inhibitors and uses thereof. The invention provides new benzonaphthyridine derivatives that inhibit PDE5 for therapeutic use in Alzheimer's disease.

Provisional 0019240.00963US3

Erfinder: Orange, O., Landry, DW, Fiorito, J., Deng, SX, Wasmuth, A.

h) Enhancing learning and memory in amyloid-β-related neurodegenerative diseases such as Alzheimer's. The invention relates to methods of increasing learning and memory in a patient with a neuropathological condition, particularly a condition associated with increased beta-amyloid deposition, the method comprising administering an effective amount of a compound that inhibits the activity of Uch. can increase to the patient includes -L1. The invention is also directed to screening methods for identifying compounds that

the activity of the proteasome system, Uch-L1, or both.

Filing date: June 29, 2006 Patent granted: US7947279 (Date of issue May 24, 2011)

Inventor: Orange , Ö. Shelanski , M. L., Gong, B.

I) New compounds with selective PDE4D inhibiting activity. The invention is directed to the synthesis of a new class of phosphodiesterase 4D inhibitors for the therapy of Alzheimer's disease

Submission date: 02.14.14 . Patentanmeldungsnummer: 14425015.6

Erfinder: Arancio, O., Fa ’, M., Prickaerts, J., Bruno, O., Fossa, P., Fedele, E., Ricciarelli, R.

l) Novel Cysteine ​​Protease Inhibitors and Uses Thereof. The invention is directed to the synthesis of a new class of calpain inhibitors for the therapy of Alzheimer's disease

Submission date: 01.02.13. Patentanmeldungsnummer: PCT/US2013/024364

Inventors: Arancio, O., Fa ’, M., Schiefer, I.T., Thatcher, G.R.

m) MAP kinase modulators and uses thereof. The invention is directed to the synthesis of a new class of p38alpah MAP kinase inhibitors against neurodegeneration.

Submission date: 03.17.14. Patentanmeldungsnummer: PCT/US2014/030260

Erfinder: Arancio, O., Watterson, D.M., Pelletier, J.C., Roy, S.M.

Committees / associations / memberships


k-means cluster analysis

Society for Neuroscience (USA)


1995-2000 New Zealand Neurological Foundation, Scientific Advisory Board (reviewed neuroscience scholarship applications from academic institutions in New Zealand)

2000 - Current Italian University Ministry, National Scientific Committee for the Evaluation of Grants (peer-reviewed research projects as an external member of a national body. Applications are in the field of neuroscience and are submitted by academic institutions in Italy)

2001 - Current Alzheimer's Association (reviewed international applications submitted for their annual research fellowship program)

2000 - Today Institute for the Study of Aging / Alzheimer's Drug Discovery Foundation (Member of the Scientific Review Board. Regularly reviewed international funding applications from science and industry. Focus on drug research in aging and Alzheimer's disease)

2002 Philip Morris (reviewed neuroscience funding applications)

2002 EFSA Ad Hoc Expert Panel on GMOs (to advise the European Food Safety Authority, which is responsible for assessing the safety of all genetically modified foods).

2003 - Current NIH: served in the following review groups for drug research (ZRG1 MDCN-C / MNPS-C, ZRG1 GGG-T) as well as in review groups for P01s and panels with a special focus

2004 - Present Wellcome Trust (reviewed grant applications. The Wellcome Trust is the largest UK charity funding innovative biomedical research in the UK and internationally)

2004-2008 Human Frontier Science Program (reviewed funding applications for postdoctoral fellowships. The organization supports novel, innovative and interdisciplinary basic research with a focus on the complex mechanisms of living organisms. A clear focus is on novel collaborations that bring biologists together with scientists from areas such as Physics, mathematics, chemistry, computer science and engineering to problems at the border of the life sciences).

2006 - Present Science Foundation Ireland (audited for Principal Investigator Program Grant. The foundation was established by the Irish government to invest significant resources in leading researchers in the fields of science and engineering)

2007 - Current Medical Research Council (MRC) (reviewed grant applications for the New Investigator Awards. The MRC is funded by the UK government and supports medical research in the UK)

2008 - Current National Medical Research Council (NMRC) (evaluated applications for Individual Research Grant. The NMRC is funded by the government of Singapore and supports medical research in Singapore)

2008 - Present Alzheimer's Society - UK (verified applications submitted as part of their annual research fellowship program)

2008 - 2012 Department of Veteran Affairs (serves in the following review group: Neurobiology D)

2011 - currently Ministero della Salute (Italy) (evaluated applications for individual research grants, program projects and industrial / university collaborations)

2011 European Research Council (evaluated applications for Individual Research Grant)

2012 - Current Research Grant Council (RGC) of Hong Kong (evaluated applications for Individual Research Grant)

2012 Czech Science Foundation (evaluated applications for Individual Research Grant)

2013 NSF (assessed applications for Individual Research Grant)

2013 - present The French National Research Agency (ANR) (evaluated applications for individual research funding)

2013 - present Dutch organization for health research and development (evaluated applications for individual research funding)

2013 - Present The W. Garfield Weston Foundation (evaluated individual research grant applications)

2014-2017 Program Committee of the Society for Neurosciences

honors and awards

1987 G. Moruzzi Fellowship, Fidia Research Foundation, Washington, D.C., USA

1990 Anna Villa Rusconi Foundation Prize, Varese, Italien

1990 Stipendium, Fidia SPA, Abano Terme, Italy

1991 Stipendium, Fidia SPA, Abano Terme, Italien

examples of endemic diseases

1991 INSERM Poste vert Fellowship, Paris, France

1994 scholarship, University of Bologna, Bologna, Italy

2001-2003 Whitehead-Stipendium

2001-2004 speaker fund for biomedical research

2004-2006 Investigator Initiated Research Award

2007 AHAF, Centennial Award

2007 Alzheimer’s Association, Zenith Award

2008 Margaret Cahn Research Award

2010 Edward N. and Della L. Thome Memorial Foundation, Prize

Research interests

  • Biophysik/Ionenkanäle
  • Neural degeneration and repair
  • Neurobiology of Disease
  • Neurobiology of Learning and Memory
  • Synapses and circuits


Koppensteiner P, Trinchese F, FÃ M, Puzzo D, Gulisano W, Yan S, Poussin A, Liu S, Orozco I, Dale E, Teich AF, Palmeri A, Ninan I, Boehm S, Arancio O. Time-dependent reversal of synaptic plasticity Induced by physiological concentrations of oligomeric Aβ42: an early index of Alzheimer's disease. Sci Rep. 2016 6: 32553. PMCID: PMC5007504

Brullo C, Ricciarelli R, Prickaerts J, Arancio O, Massa M, Rotolo C, Romussi A, Rebosio C, Marengo B, Pronzato MA, van Hagen BT, van Goethem NP, D'Ursi P, Orro A, Milanesi L, Guariento S, Cichero E, Fossa P, Fedele E, Bruno O. New findings on selective PDE4D inhibitors: 3- (Cyclopentyloxy) -4-methoxybenzaldehyde O- (2- (2,6-dimethylmorpholino) -2-oxoethyl) oxime ( GEBR.) -7b) structural development and promising activities to restore memory disorders. Eur J Med. Chem. Dr. 2016 124: 82-102. PMID: 27560284

Manassero G, Guglielmotto M, Zamfir R, Borghi R, Colombo L, Salmona M, Perry G, Odetti P, Arancio O, Tamagno E, Tabaton M. Beta-amyloid 1-42 monomers, but not oligomers, create a PHF-like Tau protein conformation. Aging cell. 2016 15: 914-23. PMCID: PMC5013016

Luo J, Lee SH, VandeVrede L, Qin Z, Ben Aissa M, Larson J, Teich AF, Arancio O, D'Souza Y, Elharram A, Koster K, Tai LM, LaDu MJ, Bennett BM, Thatcher GR. A multifunctional therapeutic approach to disease modification in several familial mouse models and a new sporadic model of Alzheimer's disease. Mol neurodegenerate. 2016 11:35, PMCID: PMC4850651

Teich AF, Sakurai M, Patel M, Holman C, Saeed F, Fiorito J, Arancio O. PDE5 exists in human neurons and is a useful therapeutic target for neurological diseases. J Alzheimers Dis., 2106 Mar. 9. [Epub before going to press] PMID: 26967220.

Nicholls, RE, Sontag, JM., Zhang, H., Staniszewski, A., Yan, S., Kim, CY, Yim, M., Woodruff, CM, Arning, E., Wasek, B., Yin, D ., Bottiglieri, T., Sontag, E., Kandel, ER, Arancio, O., PP2A methylation controls the sensitivity and resistance to β-amyloid-induced cognitive and electrophysiological impairments. Proc. Natl. Acad. Science USA, 2016 113: 3347-52. PMCID: PMC4812727.

Fá M., Puzzo D., Piacentini R., Staniszewski A., Zhang H., Baltrons MA, Li Puma DD, Chatterjee I., Li J., Saeed F., Berman HL, Ripoli C., Gulisano W. , Gonzalez J., Tian H., Costa JA, Lopez P., Davidowitz E., Yu WH, Haroutunian V., Brown LM, Palmeri A., Sigurdsson EM, Duff KE, Teich AF, Honig LS, Sierks M., Moe JG, D'Adamio L., Grassi C., Kanaan NM, Fraser PE, Arancio O. Extracellular dew oligomers cause an immediate impairment of LTP and memory. Ski-Rep. 2016 6: 19393. PMCID: PMC4726138

Luo J, Lee SH, VandeVrede L, Qin Z, Piyankarage S, Tavassoli E, Asghodom RT, Ben Aissa M, FÃ M, Arancio O, Yue L, Pepperberg DR, Thatcher GR. New development of a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA-potentiating activity for use in dementia. BMC Neurosci. 2015 16:67. PMID: 26480871.

FÃ M, Zhang H, Staniszewski A, Saeed F, Shen LW, Schiefer IT, Siklos MI, Tapadar S, Litosh VA, Libien J, Petukhov PA, Teich AF, Thatcher GR, Arancio O Novel selective calpain-1 inhibitors as potential Therapeutics in Alzheimer's Disease. J Alzheimers Dis. 2015 49: 707-21. PMID: 26484927.

Hue CD, Cho FS, Cao S, Nicholls RE, Vogel Iii EW, Sibindi C, Arancio O, Bass C ', Meaney D, Morrison III B 3. Time course and size of the opening of the blood-brain barrier in a mouse model of a blast-induced one traumatic brain injury. J neurotrauma. September 28, 2015. [Epub before printing]. PMID: 26414212

Fang D, Wang Y, Zhang Z, Du H, Yan S, Sun Q, Zhong C, Wu L, Vangavaragu JR, Yan S, Hu G, Guo L, Rabinowitz M, Glaser E, Arancio O, Sosunov AA, McKhann GM , Chen JX, Yan SS. Increased preP neuronal activity reduces Aβ accumulation, dampens neuroinflammation, and improves mitochondrial and synaptic function in the Alzheimer's mouse model. Hum Mol Genet. 2015 24: 5198-210. PMID: 26123488

Matsuzaki S, Lee L, Knock E, Srikumar T, Sakurai M, Hazrati LN, Katayama T, Staniszewski A, Raught B, Arancio O, Fraser PE. SUMO1 influences synaptic function, spinal column density and memory. Sci Rep. 2015 5: 10730. PMID: 26022678

  • Puzzo D, Gulisano W, Palmeri A, Arancio O. (2015). Rodent models for drug research in Alzheimer's disease. Expert opinion on drug research. 10: 703-711.

  • Roy SM, Grum-Tokars VL, Schavocky JP, Saeed F, Staniszewski A, et al. (2015). Targets Protein Kinases of the Human Central Nervous System: An isoform-selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's mouse models. ACS chemical neuroscience. 6: 666-680.
  • Kim S, Titcombe RF, Zhang H, Khatri L, Girma HK et al. (2015). Network compensation of the cyclic GMP-dependent protein kinase II knockout in the hippocampus by Ca2 + -permeable AMPA receptors. Proceedings of the National Academy of Sciences of the United States of America. 112: 3122-127.
  • Nestor MW, Jacob S, Sun B, Pré D, Sproul AA, et al. (2015). Characterization of a subpopulation of developing cortical interneurons from human iPSCs in serum-free embryoid bodies. American Journal of Physiology. Cell physiology. 308: C209-219.
  • Teich AF, Nicholls RE, Puzzo D, Fiorito J, Purgatorio R, et al. (2015). Synaptic Therapy in Alzheimer's Disease: a CREB-Centered Approach. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. 12: 29-41.
  • Lee L, Dale E, Staniszewski A, Zhang H, Saeed F, et al. (2014). Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer's disease. Scientific reports. 4: 7190.
  • Koppensteiner P, Böhm S, Arancio O. (2014). Electrophysiological profiles of induced neurons converted directly from adult human fibroblasts indicate incomplete neuronal conversion.
  • Cellular reprogramming. 16: 439-446.
  • Guglielmotto M, Monteleone D, Piras A, Valsecchi V, Tropiano M, et al. (2014). Aβ1-42 monomers or oligomers have different effects on autophagy and apoptosis. Autophagy. 10: 1827-1843.
  • Yan S, Li Z, Li H, Arancio O, Zhang W. (2014). Notoginsenoside R1 increases neuronal excitability and improves synapse and memory disorders after an increase in amyloids.
  • Scientific reports. 4: 6352.
  • Tang G, Gudsnuk K, Kuo SH, Cotrina ML, Rosoklija G, et al. (2014). The loss of mTOR-dependent macroautophagy causes autistic deficits in synaptic circumcision. Neuron. 83: 1131-1143.
  • Ren H, Yan S, Zhang B, Lu TY, Arancio O, et al. (2014). Glut4 expression defines an insulin-sensitive neuronal population of the hypothalamus. Molecular metabolism. 3: 452-459.
  • Origlia N, Criscuolo C, Arancio O, Yan SS, Domenici L. (2014). RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment.
  • The Journal of Neuroscience: The official journal of the Society for Neuroscience. 34: 8749-8760.
  • Puzzo D, Lee L, Palmeri A, Calabrese G, Arancio O. (2014). Behavioral Testing Using Mouse Models of Alzheimer's Disease: Practical Considerations and Guidelines. Biochemical pharmacology. 88: 450-467.
  • Ricciarelli R, Puzzo D, Bruno O, Canepa E, Gardella E, et al. (2014). A new mechanism for cyclic adenosine monophosphate-mediated memory formation: the role of amyloid beta.
  • Annals of Neurology. 75: 602-607.
  • D. Puzzo, C. Loreto, S. Giunta, G. Musumeci, G. Frasca et al. (2014). Effect of phosphodiesterase-5 inhibition on apoptosis and beta-amyloid load in aged mice. Neurobiology of Aging. 35: 520-531.
  • Pr¨ D, Nestor MW, Sproul AA, Jacob S, Koppensteiner P, et al. (2014). A time course analysis of the electrophysiological properties of neurons differentiated from human induced pluripotent stem cells (iPSCs). Plus one. 9: e103418.
  • FÃ M, Staniszewski A, Saeed F, Francis YI, Arancio O. (2014). Dynamin 1 is required for memory formation. Plus one. 9: e91954.
  • Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, et al. (2014). Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: The binding of Abeta 42 oligomers to specific neuronal receptors is being replaced by drug candidates that improve cognitive deficits. Plus one. 9: e111898.
  • Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, et al. (2014). Alzheimer's therapeutics against amyloid beta 1-42 oligomers II: Sigma-2 / PGRMC1 receptors mediate the Abeta 42 oligomer binding and synaptotoxicity. Plus one. 9: e111899.
  • Lee L, Kosuri P, Arancio O. (2014). Picomolar amyloid-β peptides enhance spontaneous calcium transients in astrocytes. Journal of Alzheimer's Disease: JAD. 38: 49-62. NIHMSID: NIHMS595742.
  • Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, et al. (2014). Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors. Plus one. 9: e84547.
  • Orozco IJ, Koppensteiner P, Ninan I, Arancio O. (2014). The schizophrenia susceptibility gene DTNBP1 modulates synaptic transmission and plasticity of AMPAR in the hippocampus of juvenile DBA / 2J mice. Molecular and Cellular Neuroscience. 58: 76-84.
  • Lee L, Sakurai M, Matsuzaki S, Arancio O, Fraser P. (2013). SUMO and Alzheimer's disease.
  • Neuromolecular Medicine. 15: 720-36.
  • Schiefer IT, Tapadar S, Litosh V, Siklos M, Scism R, et al. (2013). Design, synthesis and optimization of novel epoxides with peptidomimetics as selective calpain inhibitors.
  • Journal of Medicinal Chemistry. 56: 6054-68.
  • Knowles JK, Simmons DA, Nguyen TV, Vander Griend L, Xie Y, et al. (2013). The low molecular weight p75NTR ligand prevents cognitive deficits and the degeneration of neurites in an Alzheimer's mouse model. Neurobiology of Aging. 34: 2052-2063.
  • Fiorito J, Saeed F, Zhang H, Staniszewski A, Feng Y, et al. (2013). Synthesis of Quinoline Derivatives: Discovery of a Potent and Selective Phosphodiesterase-5 Inhibitor for the Treatment of Alzheimer's Disease. European journal of medicinal chemistry. 60: 285-294.
  • L. Xing, M. Salas, H. Zhang, J. Gittler, T. Ludwig et al. (2013). Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-marked RCAN1 (DSCR1).
  • Mammalian Genome: Official Journal of the International Mammalian Genome Society. 24: 30-43.
  • Pozueta J, Lefort R, Ribe EM, Troy CM, Arancio O, et al. (2013). Caspase-2 is required for the dendritic spine and behavioral changes in J20 APP transgenic mice. Nature communication. 4: 1939.
  • Lombino F, Biundo F, Tamayev R, Arancio O, D'Adamio L. (2013). An intracellular threonine of the amyloid-β precursor protein mediates synaptic plasticity deficits and memory loss. Plus one. 8 (2): e57120.
  • Teich AF, Patel M, Arancio O. 2013. A reliable way to detect endogenous mouse β-amyloid.
  • More eins. 8: e55647.
  • Puzzo D, Arancio O. (2013). Amyloid β peptide: Dr. Jekyll or Mr. Hyde? Journal of Alzheimer's Disease: JAD. 33 Supplement 1: S111-20. NIHMSID: NIHMS483269.
  • Watterson DM, Grum-Tokars VL, Roy SM, Schavocky JP, Bradaric BD, et al. (2013). Development of new in vivo chemical probes to treat the involvement of CNS protein kinase in synaptic dysfunction. Plus one. 8: e66226.
  • Tamayev R, Akpan N, Arancio O, Troy CM, D'Adamio L. (2012). Caspase-9 mediates synaptic plasticity and memory deficits in Danish dementia knock-in mice: Caspase-9 inhibition offers therapeutic protection. Molecular Neurodegeneration. 7:60. PubMed
  • McIntire LB, Berman DE, Myaeng J, Staniszewski A, Arancio O, et al. (2012). The reduction of synaptojanin 1 improves synaptic and behavioral disorders in a mouse model of Alzheimer's disease. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 32: 15271-6.
  • Teich AF, Arancio O. (2012). Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? The biochemical journal. 446: 165-177.
  • Liu X, Betzenhauser MJ, Reiken S, Meli AC, Xie W, et al. (2012). Role of leaky ryanodine neuronal receptors in stress-induced cognitive dysfunction. Cell. 150: 1055-1067. NIHMSID: NIHMS402231.
  • Z. Qin, J. Luo, L. VandeVrede, E. Tavassoli, M. Fa et al. (2012). Design and synthesis of neuroprotective methylthiazoles and modification as NO chimeras for neurodegenerative therapy. Journal of Medicinal Chemistry. 55: 6784-6801.
  • Ren H, Orozco IJ, Su Y, Suyama S, Gutiérrez-Juérez R, et al. (2012). The FoxO1 target Gpr17 activates AgRP neurons to regulate food intake. Cell. 149: 1314-1326.
  • Gaisler-Salomon I, Wang Y, Chuhma N, Zhang H, Golumbic YN et al. (2012). Synaptic basis of altered hippocampal function in mice with glutaminase deficiency during maturation.
  • Hippocampus. 22:1027-1039.
  • Slate IT, VandeVrede L, Fa'M, Arancio O, Thatcher GR. (2012). Furoxanes (1,2,5-oxadiazole-N-oxides) as novel NO-mimetic neuroprotective and procognitive agents. Journal of Medicinal Chemistry. 55: 3076-3087.
  • Tamayev R, Matsuda S, Arancio O, D'Adamio L. (2012). The β- but not the γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Molecular Medicine. 4: 171-179.
  • Hashimoto G, Sakurai M, Teich AF, Saeed F, Aziz F, et al. (2012). The stimulation of the 5-HTÃâ € šâ € ž receptor leads to the production of soluble AβPPα through MMP-9 upregulation. Journal of Alzheimer's Disease: JAD. 32: 437-445.
  • AM Duffy, MJ Schaner, SH Wu, A. Staniszewski, A. Kumar et al. (2011). A selective role for the ARMS / Kidins220 scaffold protein in spatial memory and trophic support of entorhinal and frontal cortical neurons. Experimental neurology. 229: 409-420.
  • Tamayev R, Matsuda S, Giliberto L, Arancio O, D'Adamio L. (2011). APP heterozygosity prevents memory deficits in knockin mice expressing the Danish dementia BRI2 mutant. The EMBO journal. 30: 2501-2509.
  • D. Puzzo, L. Privitera, M. Fa, A. Staniszewski, G. Hashimoto et al. (2011). Endogenous amyloid-β is necessary for synaptic plasticity and memory of the hippocampus. Annals of Neurology. 2011; 69: 819-30.
  • J. Yao, H. Du, S. Yan, F. Fang, C. Wang et al. (2011). Inhibition of the amyloid beta (Abeta) peptide binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 31: 2313-2320.
  • Wu SH, Arévalo JC, Neubrand VE, Zhang H, Arancio O, et al. (2010). The Ankyrin Repeat-rich Membrane Spanning (ARMS) / Kidins220 scaffold protein is regulated by activity-dependent calpain proteolysis and modulates synaptic plasticity. The journal for biological chemistry. 285: 40472-40478.
  • Oliveira TG, Chan RB, Tian H, Laredo M, Shui G, et al. (2010). Phospholipase d2 ablation improves synaptic dysfunction and cognitive deficits associated with Alzheimer's disease. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 30: 16419-16428.
  • Tamayev R, Matsuda S, FÃ M, Arancio O, D'Adamio L. (2010). Danish demented mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits. Proceedings of the National Academy of Sciences of the United States of America. 107: 20822-20827.
  • Tamayev R, Giliberto L, Li W, d'Abramo C, Arancio O, et al. (2010). Memory deficits due to the familial British dementia BRI2 mutation are caused by loss of BRI2 function rather than amyloidosis. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 30: 14915-14924.
  • Arévalo JC, Wu SH, Takahashi T, Zhang H, Yu T, et al. (2010). The ARMS / Kidins220 scaffold protein modulates synaptic transmission. Molecular and Cellular Neuroscience. 45: 92-100.
  • Origlia N., Bonadonna C, Rosellini A, Leznik E, Arancio O, et al. (2010). Microglial receptor for the end product-dependent signaling pathway of advanced glycation drives beta-amyloid-induced synaptic depression and long-term depression disorder in the entorhinal cortex. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 30: 11414-11425.
  • Fa M, Orozco IJ, Francis YI, Saeed F, Gong Y, et al. (2010). Production of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity disorder on hippocampal slices. Journal of Visualized Experiments: JoVE. (41) doi: 10.3791 / 1884.
  • Origlia N, Arancio O, Domenici L, Yan SS. (2009). MAPK, beta amyloid, and synaptic dysfunction: the role of RAGE. Expert evaluation of neurotherapeutic agents. 9): 1635-1645.
  • Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. (2009). Reversal of long-term dendritic spine changes in Alzheimer's models. Proceedings of the National Academy of Sciences of the United States of America. 106: 16877-16882.
  • Gaisler-Salomon I., Miller GM, Chuhma N., Lee S., Zhang H, et al. (2009). Glutaminase-deficient mice show hippocampal hypoactivity, insensitivity to propsychotic drugs and potentiated latent inhibition: relevance for schizophrenia. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 34: 2305-2322.
  • D. Puzzo, A. Staniszewski, SX Deng, L. Privitera, E. Leznik et al. (2009). Inhibition of phosphodiesterase 5 improves synaptic function, memory, and amyloid beta load in a mouse model of Alzheimer's disease. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 29: 8075-8086.
  • Basavarajappa BS, Nixon RA, Arancio O. (2009). Endocannabinoid System: Emerging Role From Neurodevelopment To Neurodegeneration. Mini-Reviews in Medicinal Chemistry. 9: 448-462.
  • Vitolo O, Gong B, Cao Z, Ishii H, Jaracz S, et al. (2009). Protection against beta-amyloid-induced abnormal synaptic function and cell death by ginkgolid J. Neurobiology of aging. 30: 257-265.
  • Origlia N., Capsoni S., Cattaneo A, Fang F, Arancio O, et al. (2009). Abeta-dependent inhibition of LTP in various intracortical circuits of the visual cortex: the role of RAGE. Journal of Alzheimer's Disease: JAD. 17: 59-68.
  • Francis YI, FÃ M, Ashraf H, Zhang H, Staniszewski A, et al. (2009). Dysregulation of histone acetylation in the APP / PS1 mouse model of Alzheimer's disease. Journal of Alzheimer's Disease: JAD. 18: 131-139.
  • D. Puzzo, L. Privitera, E. Leznik, M. F., A. Staniszewski et al. (2008). Picomolar amyloid beta positively modulates synaptic plasticity and memory in the hippocampus. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 28: 14537-14545.
  • Basavarajappa BS, Ninan I, Arancio O. (2008). Acute ethanol suppresses glutamatergic neurotransmission by endocannabinoids in hippocampal neurons. Journal of Neurochemistry. 107 (4): 1001-13.
  • H. Du, L. Guo, F. Fang, D. Chen, AA Sosunov et al. (2008). Cyclophilin-D deficiency weakens mitochondrial and neural disorders and improves learning and memory in Alzheimer's disease. Natural medicine. 14: 1097-105.
  • Trinchese F, Fa 'M, Liu S, Zhang H, Hidalgo A, et al. (2008). Inhibiting calpains improves memory and synaptic transmission in a mouse model of Alzheimer's disease. The Journal of Clinical Investigations. 118: 2796-807.
  • Arancio O. (2008). PIP2: a new major player in Alzheimer's disease. Cell science. 5: 44-47.
  • SV Voronov, SG Frere, S. Giovedi, EA Pollina, C. Borel et al. (2008). Synaptojanin-1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down syndrome.
  • Proceedings of the National Academy of Sciences of the United States of America. 105:9415-20.
  • Serulle Y, Arancio O, Paragraph EB. (2008). A role of cGMP-dependent protein kinase II in AMPA receptor traffic and synaptic plasticity. Canals (Austin, Texas). 2: 230-2.
  • L. Liu, I.J. Orozco, E. Planel, Y. Wen, A. Bretteville et al. (2008). A transgenic rat that develops Alzheimer's-like amyloid pathology, deficits in synaptic plasticity, and cognitive impairment. Neurobiology of Disease. 31: 46-57.
  • Muhammad A., Flores I., Zhang H., Yu R., Staniszewski A, et al. (2008). Retro-shortage seen in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proceedings of the National Academy of Sciences of the United States of America. 105: 7327-32.
  • Berman DE, Dall'Armi C, Voronov SV, McIntire LB, Zhang H, et al. (2008). Oligomeric amyloid-beta-peptide disrupts the phosphatidylinositol-4,5-bisphosphate metabolism. Natural neuroscience. 2008; 11 (5): 547-54.
  • Puzzo D, Sapienza S, Arancio O, Palmeri A. (2008). Phosphodiesterase 5 role in synaptic plasticity and memory. Neuropsychiatric Disorder and Treatment. 4: 371-87.
  • Y. Matsuoka, Y. Jouroukhin, A.J. Gray, L. Ma, C. Hirata-Fukae, et al. (2008). A neural microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and improves cognitive function in a mouse model of Alzheimer's disease. The Journal of Pharmacology and Experimental Therapeutics. 325: 146-53.
  • Origlia N., Righi M., Capsoni S., Cattaneo A, Fang F, et al. (2008). Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 28: 3521-30.
  • Yang T, Knowles JK, Lu Q, Zhang H, Arancio O, et al. (2008). Small molecule, non-peptidic p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. Plus one. 3: e3604.
  • Echeverria V, Berman DE, Arancio O. (2007). Beta-amyloid peptide oligomers inhibit BDNF-induced arc expression in cultured cortical neurons. Current Alzheimer's Research. 4: 518-21.
  • Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, et al. (2007). RAGE: a potential target for Abeta-mediated cellular disorders in Alzheimer's disease. Current Molecular Medicine. 7: 735-42.
  • Y. Serulle, S. Zhang, I. Ninan, D. Puzzo, M. McCarthy et al. (2007). A GluR1-cGKII interaction regulates AMPA receptor traffic. Neuron. 56: 670-88.
  • Arancio O, Chao MV. (2007). Neurotrophins, Synaptic Plasticity, and Dementia. Current opinion in neurobiology. 17: 325-30.
  • Liu S, Fa M, Ninan I, Trinchese F, Duration W, et al. (2007). Alpha-synuclein involvement in synaptic plasticity of the hippocampus: role of NO, cGMP, cGK, and CaMKII. The European Journal of Neuroscience. 25: 3583-96.
  • Ninan I, Liu S, Rabinowitz D, Arancio O. (2006). Early presynaptic changes during plasticity in cultured hippocampal neurons. The EMBO journal. 25: 4361-71.
  • Ninan I, Arancio O, Rabinowitz D. (2006). Estimation of the mean value from sums with an unknown number of summands. Biometrics. 62: 918-20.
  • Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, et al. (2006). Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 126: 775-88.
  • Yano H, Ninan I, Zhang H, Milner TA, Arancio O, et al. (2006). BDNF-mediated neurotransmission is based on a myosin VI motor complex. Natural neuroscience. 9: 1009-18.
  • Puzzo D, Arancio O. (2006). Fibrillary beta-amyloid affects the late phase of long-term potentiation. Current Alzheimer's Research. 3: 179-83.
  • Moretti P, Levenson JM, Battaglia F, Atkinson R, Teague R, et al. (2006). Learning and memory as well as synaptic plasticity are impaired in a mouse model of Rett syndrome. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 26: 319-27.
  • Puzzo D, Palmeri A, Arancio O. (2006). Involvement of the nitric oxide pathway in synaptic dysfunction after amyloid elevation in Alzheimer's disease Reviews in Neuroscience. 17: 497-523.
  • D. Puzzo, O. Vitolo, F. Trinchese, J. P. Jacob, A. Palmeri et al. (2005). Amyloid beta peptide inhibits the activation of the nitric oxide / cGMP / cAMP-responsive element-binding protein pathway during synaptic plasticity of the hippocampus. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 25: 6887-97.
  • K. Takuma, J. Yao, J. Huang, H. Xu, X. Chen et al. (2005). ABAD intensifies the Abeta-induced cell stress through mitochondrial dysfunction. FASEB Journal: official publication of the Federation of American Societies for Experimental Biology. 19: 597-8.
  • H. Zhang, B. Gong, S. Liu, M. Fa, I. Ninan et al. (2005). Synaptic exhaustion is more pronounced in the transgenic mouse model APP / PS1 of Alzheimer's disease. Current Alzheimer's Research. 2: 137-40.
  • Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, et al. (2004). Sustained improvement in synaptic and cognitive functions in an Alzheimer's mouse model after rolipram treatment. The Journal of Clinical Investigations. 114: 1624-34.
  • S. Liu, I. Ninan, I. Antonova, F. Battaglia, F. Trinchese et al. (2004). Alpha-Synuclein causes a long-lasting increase in neurotransmitter release. The EMBO journal. 23: 4506-16.
  • O. Arancio, HP Zhang, X. Chen, C. Lin, F. Trinchese et al. (2004). RAGE potentiates the Abeta-induced disruption of neuronal function in transgenic mice. The EMBO journal. 23: 4096-105.
  • Veeranna, T. Kaji, B. Boland, T. Odrljin, P. Mohan et al. (2004). Calpain mediates the calcium-induced activation of the Erk1,2-MAPK signaling pathway and the phosphorylation of the cytoskeleton in neurons: relevance for Alzheimer's disease. The American Journal of Pathology. 165: 795-805.
  • F. Trinchese, S. Liu, F. Battaglia, S. Walter, PM Mathews et al. (2004). Progressive age-related development of Alzheimer's-like pathology in APP / PS1 mice. Annals of Neurology. 55: 801-14.
  • JW Lustbader, M. Cirilli, C. Lin, HW Xu, K. Takuma et al. (2004). ABAD links Abeta directly to mitochondrial toxicity in Alzheimer's disease. Science (New York, N.Y.) 304: 448-52.
  • Ninan I., Arancio O. (2004). Presynaptic CaMKII is necessary for synaptic plasticity in cultured hippocampal neurons. Neuron. 42: 129-41.
  • Trinchese F, Liu S, Ninan I, Puzzo D, Jacob JP, et al. (2004). Cell cultures from animal models of Alzheimer's disease as a tool for faster drug screening and testing. Journal of Molecular Neuroscience: MN. 24: 15-21.
  • Di Rosa G, Puzzo D, Sant'Angelo A, Trinchese F, Arancio O. (2003). Alpha-Synuclein: between synaptic function and dysfunction. Histology and histopathology. 18: 1257-66.
  • Petrone A, Battaglia F, Wang C, Dusa A, Su J, et al. (2003). The receptor protein tyrosine phosphatase alpha is essential for neuronal migration in the hippocampus and long-term potentiation.
  • The EMBO journal. 22: 4121-31.
  • Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, et al. (2003). The prerequisite for hippocampal neurogenesis for the behavioral effects of antidepressants. Science (New York, N.Y.) 301: 805-9.
  • Sant'Angelo A, Trinchese F, Arancio O. (2003). Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease. Neurochemical Research. 28: 1009-15.
  • Battaglia F, Trinchese F, Liu S, Walter S, Nixon RA, et al. (2003). Calpain Inhibitors, a Treatment for Alzheimer's Disease: Position Paper. Journal of Molecular Neuroscience: MN. 20: 357-62.
  • Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, et al. (2002). Amyloid beta peptide inhibition of the PKA / CREB signaling pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proceedings of the National Academy of Sciences of the United States of America. 99: 13217-21.
  • Di Rosa G, Odrijin T, Nixon RA, Arancio O. (2002). Calpain inhibitors: a treatment for Alzheimer's disease. Journal of Molecular Neuroscience: MN. 19: 135-41.
  • Antonova I, Arancio O, Trillat AC, Wang HG, Zablow L, et al. (2001). Rapid rise in clusters of presynaptic proteins at the beginning of long-lasting potentiation. Science (New York, N.Y.) 294: 1547-50.
  • Arancio O, Antonova I, Gambaryan S, Lohmann SM, Wood JS et al. (2001). Presynaptic role of cGMP-dependent protein kinase during long-term potentiation. The Journal of Neuroscience: The official journal of the Society for Neuroscience. 21: 143-9.
  • Agnihotri N., López-García JC, Hawkins RD, Arancio O. (1998). Morphological changes associated with long-term potentiation. Histology and histopathology. 13: 1155-62.
  • Son H, Lu YF, Zhuo M, Arancio O, Kandel ER, et al. (1998). The specific role of cGMP in hippocampal LTP. Learning & Memory (Cold Spring Harbor, N.Y.). 5: 231-45.
  • Hawkins RD, Son H, Arancio O. (1998). Nitric oxide as a retrograde messenger substance during long-term potentiation in the hippocampus. Advances in brain research. 118: 155-72.
  • O Arancio, M. Kiebler, CJ Lee, V. Lev-Ram, RY Tsien et al. (1996). Nitric oxide acts directly in the presynaptic neuron to cause long-term potentiation in cultivated hippocampal neurons. Cell. 87: 1025-35.
  • Pasino E., Buffelli M, Arancio O, Busetto G, Salviati A, et al. (1996). Effects of a long-term conduction blockage on the membrane properties of reinnervated and normally innervated rat skeletal muscles. The journal of physiology. 497: 457-72.
  • López-García JC, Arancio O, Kandel ER, Baranes D. (1996). A presynaptic locus for the long-term potentiation of the elementary synaptic transmission at moss fiber synapses in culture. Proceedings of the National Academy of Sciences of the United States of America. 93: 4712-7.
  • Arancio O., Lev-Ram V., Tsien RY, Kandel ER, Hawkins RD. (1996). Nitric oxide acts as a retrograde messenger substance during long-term potentiation in cultivated hippocampal neurons. Journal of Physiology, Paris. 90: 321-2.
  • Arancio O, Kandel ER, Hawkins RD. (1995). Activity-dependent long-term enhancement of transmitter release by presynaptic 3 ', 5'-cyclic GMP in cultured hippocampal neurons. Nature. 376: 74-80.
  • O. Arancio, H. Korn, A. Gulyas, T. Freund, R. Miles (1995). Excitatory synaptic connections to inhibitory cells of the rat hippocampus may comprise a single transmitter release site. The journal of physiology. 481: 395-405.
  • Hawkins RD, Zhuo M, Arancio O. (1994). Nitric oxide and carbon monoxide as possible retrograde messengers in long-term hippocampal potentiation. Journal of Neurobiology. 25: 652-65.
  • Arancio O, Yoshimura M, Murase K, MacDermott AB. (1993). The distribution of excitatory amino acid receptors on acutely dissociated dorsal horn neurons from postnatal rats.
  • Neuroscience. 52: 159-67.
  • O Arancio, M. Buffelli, A. Cangiano, E. Pasino (1992). Nerve blunt effects in the muscle are independent of synaptic connections and correlate over time with nerve degeneration phenomena. Neuroscience Letters. 146: 1-4.
  • O'Dell TJ, Hawkins RD, Kandel ER, Arancio O. (1991). Tests on the role of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proceedings of the National Academy of Sciences of the United States of America. 88: 11285-9.
  • Yoshimura M, Murase K, Arancio O, MacDermott AB. (1991). Glutamate receptor agonist-induced inward currents in spinal dorsal horn neurons dissociated from the adult rats. Neuroscientific Research. 12: 528-35.
  • Arancio O, MacDermott AB. (1991). Differential distribution of excitatory amino acid receptors on rat embryonic spinal cord neurons in culture. Journal of Neurophysiology. 65: 899-913.
  • Tiedge H, Fremeau RT Jr, Weinstock PH, Arancio O, Brosius J. (1991). Dendritische Position der neuralen BC1-RNA. Proceedings of the National Academy of Sciences of the United States of America. 88:2093-7.
  • MacDermott AB, Reichling DB, Arancio O. (1990). Mechanisms underlying the calcium input into cultured neurons from the embryonic rat spinal cord caused by excitatory amino acids.
  • Advances in Experimental Medicine and Biology. 268: 117-24.
  • O. Arancio, G. Bonadonna, M. Calvani, P. Giovene, G. Tomelleri et al. (1989). Temporary L-carnitine depletion in the skeletal muscle of rats due to D-carnitine. Pharmacological Research: the official journal of the Italian Pharmacological Society. 21: 163-8.
  • Arancio O, Cangiano A, De Grandis D (1989). Fibrillatory activity and other membrane changes in partially denervated muscles. Muscle & nerves. 12: 149-53.
  • O. Arancio, LG Bongiovanni, G. Bonadonna, G. Tomelleri, D. De Grandis (1988). Congenital muscular dystrophy and cerebellar worm genesis in two brothers. Italian journal of neurological sciences. 9: 485-9
  • Provenzano C, Arancio O, Evoli A, Rocca B, Bartoccioni E, et al. (1988). Familial autoimmune myasthenia gravis with various pathogenetic antibodies. Journal of Neurology, Neurosurgery, and Psychiatry. 51: 1228-30.
  • Arancio O, Cangiano A, Magherini PC, Pasino E. (1988). Effects of reinnervation with normal and tetrodotoxin-inactive nerves on the resting membrane potential of the skeletal muscles of rats.
  • Neuroscience Letters. 88: 179-83.
  • De Grandis D, Arancio O, Serra G. (1986). An electroneurographic answer. Muscle & nerves. 9: 185-6.
  • Polo A, Arancio O, Bronzato P, Serra G, De Grandis D. (1986). Effects of aging on visually evoked oscillatory potentials in humans. [To press]. Flow. Ital. EEG Neurofisiol. Clin.
  • Arancio O., Bongiovanni LG, De Grandis D. (1985). Acute peroneal compartment syndrome. Report on a case. European neurology. 24: 69-72.
  • Orange O, Cangiano A, Magherini PC. (1982). Role of NGF in primary sensory neuron development in the rat. Bulletin of the Italian Society for Experimental Biology. 58: 60-5.

For a full list of publications, see PubMed.gov

Interesting Articles

Editor'S Choice

The science of the flu shot
The science of the flu shot
Once in the air with the autumn cold, flu vaccinations are being given out in clinics and pharmacies across the country. Vaccination, while imperfect, is the most reliable way to avoid a potentially fatal infection. While many accept it as a seasonal inconvenience, the flu kills about 19,000 Americans in an average year. After the pioneering work of Hilary Koprowski,
Alumni publish 'Semper Fi' with Jai Courtney in the lead role
Alumni publish 'Semper Fi' with Jai Courtney in the lead role
Three Columbia alumni released Semper Fi earlier this month, a feature film starring Jai Courtney and distributed by Lionsgate. The film was produced by Alumna Karina Miller '04, co-written by Alumna Sean Mullin '06, and co-written and directed by Alumna Henry-Alex Rubin '95.
Columbia filmmakers make a splash at the Nashville Film Festival
Columbia filmmakers make a splash at the Nashville Film Festival
Current student Asad Farooqui and alumna Fany de la Chica '18 are represented at this year's Nashville Film Festival.
Review: 'The Emperor of All Diseases
Review: 'The Emperor of All Diseases'
It's difficult, if not impossible, to reach middle age without seeing the ravages of cancer up close.
Alexandra Carter
Alexandra Carter
As director of the Law School's Mediation Clinic, Alexandra Carter ’03 has been training students in various forms of alternative dispute resolution since 2008. Under her guidance, students learn negotiation strategies and advise clients in federal, state, and New York courts; Cases range from family business disputes to complaints filed with the U.S. Equal Employment Opportunity Commission. In 2016, Carter partnered with the United Nations Institute for Education and Research and their students are the exclusive providers of alternative dispute resolution classes for the United Nations Diplomatic Corps in New York. She is currently training judicial and administrative directors in New York state courts which will soon require most civil disputes to be resolved through alleged mediation rather than in public courts. In 2019, Columbia University honored Carter with the Presidential Award for Teaching for its innovative pedagogy and commitment to its students. Carter developed her passion for mediation and teaching as a student at the Law School's Mediation Clinic, led by Professor Carol Liebman, who became her mentor and role model. As a student, Carter won the Jane Marks Murphy Prize for Clinical Advocacy and the Lawrence S. Greenbaum Prize for Best Oral Argument in the 2002 Harlan Fiske Stone Moot Court Competition. Prior to enrolling in Law School, Carter was a private equity analyst with Goldman Sachs and Fulbright Fellow in Taiwan, where she researched contemporary literature to assess cross-strait political tensions. After Carter got her J.D. received, she worked on the U.S. District Court for the District of Massachusetts and then joined Cravath, Swaine & Moore as a litigator. She was retired to the academy by Liebman and other mentors from Columbia Law School. Carter's new take on negotiation is the subject of her upcoming general interest book Ask for More: 10 Questions to Negotiate Anything, which will be the main title published by Simon & Schuster in May 2020.
Ars Nova announces Melis Aker '18 as a resident of Play Group 2019
Ars Nova announces Melis Aker '18 as a resident of Play Group 2019
Alumna Melis Aker '18 joins Alumna Julia May Jonas '12 as a new member of the Ars Nova Plays Group 2019. The Play Group is a two-year residency where members become part of the Ars Nova resident artist community.
Clinic for Rehabilitation and Regenerative Medicine
Clinic for Rehabilitation and Regenerative Medicine
What are tendonitis and tendinitis? Tendons are strong strands of tissue that connect muscles to bones. Tendonitis is when a tendon is inflamed. It can hit any tendon in the body. When a tendon is inflamed, it can cause swelling, pain, and discomfort. Another problem called tenosynovitis is linked to tendonitis. This is the inflammation of the lining of the tendon sheath around a tendon. Usually the vagina is inflamed by itself, but both the vagina and tendon can be inflamed at the same time.